APA (7th ed.) Citation

Adjei, A., Beg, M., Melear, J., Thompson, J., Tsai, F., Baranda, J., . . . Sarantopoulos, J. (2020). 536MO A phase I, first-in-human, safety, pharmacokinetic, and pharmacodynamic study of oral dubermatinib (TP-0903) in patients with advanced solid tumours. Annals of Oncology, 31, S469. https://doi.org/10.1016/j.annonc.2020.08.650

Chicago Style (17th ed.) Citation

Adjei, A.A, et al. "536MO A Phase I, First-in-human, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral Dubermatinib (TP-0903) in Patients with Advanced Solid Tumours." Annals of Oncology 31 (2020): S469. https://doi.org/10.1016/j.annonc.2020.08.650.

MLA (9th ed.) Citation

Adjei, A.A, et al. "536MO A Phase I, First-in-human, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral Dubermatinib (TP-0903) in Patients with Advanced Solid Tumours." Annals of Oncology, vol. 31, 2020, p. S469, https://doi.org/10.1016/j.annonc.2020.08.650.